These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37990895)

  • 21. [Synergistic effect of polysaccharide from
    Li P; Yuan P; Que Y; Liu X; Wang G
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Apr; 41(4):504-513. PubMed ID: 33963708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostaglandin F
    Wang YJ; Xie XL; Liu HQ; Tian H; Jiang XY; Zhang JN; Chen SX; Liu T; Wang SL; Zhou X; Jin XX; Liu SM; Jiang HQ
    World J Gastroenterol; 2023 Oct; 29(39):5452-5470. PubMed ID: 37900995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability.
    Zhou S; Peng J; Xiao L; Zhou C; Fang Y; Ou Q; Qin J; Liu M; Pan Z; Hou Z
    Cell Death Dis; 2021 May; 12(5):463. PubMed ID: 33966039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metformin increases the cytotoxicity of oxaliplatin in human DLD-1 colorectal cancer cells through down-regulating HMGB1 expression.
    Huang WS; Lin CT; Chen CN; Chang SF; Chang HI; Lee KC
    J Cell Biochem; 2018 Aug; 119(8):6943-6952. PubMed ID: 29737584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
    Iveson T; Boyd KA; Kerr RS; Robles-Zurita J; Saunders MP; Briggs AH; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Pearson S; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan H; Paul J
    Health Technol Assess; 2019 Dec; 23(64):1-88. PubMed ID: 31852579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanoparticles Loaded with Platinum Drugs for Colorectal Cancer Therapy.
    Buyana B; Naki T; Alven S; Aderibigbe BA
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
    Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
    J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor pH-functionalized and charge-tunable nanoparticles for the nucleus/cytoplasm-directed delivery of oxaliplatin and miRNA in the treatment of head and neck cancer.
    Lo YL; Lin HC; Tseng WH
    Acta Biomater; 2022 Nov; 153():465-480. PubMed ID: 36115656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
    Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y
    Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New Trends in Liposome-based Drug Delivery in Colorectal Cancer.
    Krajewska JB; Bartoszek A; Fichna J
    Mini Rev Med Chem; 2019; 19(1):3-11. PubMed ID: 30179131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Precision medicine-guided co-delivery of ASPN siRNA and oxaliplatin by nanoparticles to overcome chemoresistance of colorectal cancer.
    Huang CZ; Zhou Y; Tong QS; Duan QJ; Zhang Q; Du JZ; Yao XQ
    Biomaterials; 2022 Nov; 290():121827. PubMed ID: 36228517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-dose orlistat promotes the therapeutic effect of oxaliplatin in colorectal cancer.
    Zhang Q; Zhou Y; Feng X; Gao Y; Huang C; Yao X
    Biomed Pharmacother; 2022 Sep; 153():113426. PubMed ID: 36017794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current Advances in Chitosan Nanoparticles Based Oral Drug Delivery for Colorectal Cancer Treatment.
    Choukaife H; Seyam S; Alallam B; Doolaanea AA; Alfatama M
    Int J Nanomedicine; 2022; 17():3933-3966. PubMed ID: 36105620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dihydrotanshinone I Inhibits the Proliferation and Growth of Oxaliplatin-Resistant Human HCT116 Colorectal Cancer Cells.
    Wang M; Xiang Y; Wang R; Zhang L; Zhang H; Chen H; Luan X; Chen L
    Molecules; 2022 Nov; 27(22):. PubMed ID: 36431875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of Dicer in regulating oxaliplatin resistance of colon cancer cells.
    Lai HH; Lin LJ; Hung LY; Chen PS
    Biochem Biophys Res Commun; 2018 Nov; 506(1):87-93. PubMed ID: 30336979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanocarrier System for Increasing the Therapeutic Efficacy of Oxaliplatin.
    Alavi N; Rezaei M; Maghami P; Fanipakdel A; Avan A
    Curr Cancer Drug Targets; 2022; 22(5):361-372. PubMed ID: 35048809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro and in vivo combinatorial anticancer effects of oxaliplatin- and resveratrol-loaded N,O-carboxymethyl chitosan nanoparticles against colorectal cancer.
    Wang Y; Ma J; Qiu T; Tang M; Zhang X; Dong W
    Eur J Pharm Sci; 2021 Aug; 163():105864. PubMed ID: 33965502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo Evaluation of a Novel Estrogen-Targeted PEGylated Oxaliplatin Liposome for Gastric Cancer.
    Sun Y; Xie Y; Tang H; Ren Z; Luan X; Zhang Y; Zhu M; Lv Z; Bao H; Li Y; Liu R; Shen Y; Zheng Y; Pei J
    Int J Nanomedicine; 2021; 16():8279-8303. PubMed ID: 34992365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel estrogen-targeted PEGylated liposome co-delivery oxaliplatin and paclitaxel for the treatment of ovarian cancer.
    Xie Y; Ren Z; Chen H; Tang H; Zhu M; Lv Z; Bao H; Zhang Y; Liu R; Shen Y; Zheng Y; Miao D; Guo X; Chen H; Wang S; Pei J
    Biomed Pharmacother; 2023 Apr; 160():114304. PubMed ID: 36724638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. OXA-CuS@UiO-66-NH
    Gholami M; Hekmat A; Khazaei M; Darroudi M
    J Mater Sci Mater Med; 2022 Feb; 33(3):26. PubMed ID: 35226206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.